Title : Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer.

Pub. Date : 2018 Jul 2

PMID : 29787277






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens
2 Functional analysis and molecular studies suggest that protein mutation and dysregulation of survival signaling molecules such as epidermal growth factor receptor, vascular endothelial growth factor receptor 2, and Akt contribute to tamoxifen resistance. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens
3 We employ dual drugs, ZD6474, and epigallocatechin gallate (EGCG) that inhibit EGFR2, VEGFR2, and Akt signaling pathways since changes in these signaling pathways confer tamoxifen resistance in MCF 7 and T-47D cells. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens